Characterization of the immune response in patients with urothelial cell carcinoma of the bladder and during the BCG immunotherapy of bladder cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00003700

Enrollment

500

Registered

2012-04-04

Start date

2010-04-14

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C67

Interventions

Group 1: Patients with different stages and grading of urothelial cancer of the bladder undergoing all therapy options are included Group 2: Healthy donors are used as control group

Eligibility

Sex/Gender

All

Age

1 Years to 100 Years

Inclusion criteria

Inclusion criteria: All patients undergoing treatment for urothelial cancer in the urologic department

Exclusion criteria

Exclusion criteria: Patients with compromised immune status, eg. AIDS, aquired immunodeficiency

Design outcomes

Primary

Measure	Time frame
Identification of a serological marker for bladder cancer	—

Countries

Germany

Contacts

Public ContactPeter Ardelt

Chirurgische Universitätsklinik, Abteilung für Urologie

peter.ardelt@usb.ch0761 270 28930

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026